Table 1 Demographics of patients seen for hydroxychloroquine screening.
From: Trends and practices following the 2016 hydroxychloroquine screening guidelines
Patients on HCQ (n = 166) | |
|---|---|
Sex | |
Female (%) | 150 (90.4%) |
Male (%) | 16 (9.6%) |
Race | |
Asian (%) | 24 (14.5%) |
Black or African American (%) | 7 (4.2%) |
Other or mixed race (%) | 50 (30.1%) |
Unknown (%) | 4 (2.4%) |
White (%) | 81 (48.8%) |
Estimated age starting HCQ in years | |
Mean (CI) | 44.2 (41.7, 46.8) |
Weight in kg | |
Mean (CI) | 71.7 (68.9, 74.6) |
Duration of therapy in years | |
Mean (CI) | 5.3 (4.4, 6.1) |
Estimated daily dose in mg/kg | |
Mean (CI) | 5.2 (5.0, 5.5) |
Cumulative dose in grams | |
Mean (CI) | 684.4 (568.5, 800.4) |
High-riska | |
No (%) | 110 (66.7%) |
Yes (%) | 55 (33.3%) |
SD-OCT screen | |
No (%) | 7 (4.2%) |
Yes (%) | 159 (95.8%) |
FAF screen | |
No (%) | 18 (10.8%) |
Yes (%) | 148 (89.2%) |
HVF screen | |
No (%) | 47 (28.3%) |
Yes (%) | 119 (71.7%) |
